ATC codes:
J01CR02
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis
ICD11 code:
ML32.00
INN
Amoxicillin + clavulanic acid
Medicine type
Chemical agent
Antibiotic groups
List type
Core
(EML)
(EMLc)
(EMLc)
Additional notes
For use only in combination with meropenem or imipenem + cilastatin (EML). For use only in combination with meropenem (EMLc)
Formulations
Oral > Liquid:
250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
(EMLc)
Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc)
Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc)
Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of amoxicillin + clavulanic acid 250 mg + 62.5 mg dispersible tablets to the EMLc.